Poseida Therapeutics, Inc. (PSTX)
| Market Cap | 531.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -129.78M |
| Shares Out | 36.00M |
| EPS (ttm) | -3.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $8.55 |
| Previous Close | $8.90 |
| Change ($) | -0.35 |
| Change (%) | -3.93% |
| Day's Open | 8.93 |
| Day's Range | 8.38 - 8.90 |
| Day's Volume | 113,492 |
| 52-Week Range | 7.63 - 17.62 |
SAN DIEGO, April 8, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...
SAN DIEGO, March 23, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ...
SAN DIEGO, March 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ...
A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biophar...
The biotech reported pipeline progress at its virtual R&D Day.
SAN DIEGO, Dec. 5, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell a...
SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologi...
SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technolo...
SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $PSTX #PSTX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $PSTX #PSTX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc.
SAN DIEGO--(BUSINESS WIRE)---- $GNUS #ClassAction--Shareholder rights law firm Robbins LLP is investigating whether Poseida Therapeutics, Inc. (NASDAQ: PSTX) and its officers and directors violated secu...
SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc.
NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Poseida Therapeutics, Inc.
Poseida Therapeutics Inc. (NASDAQ: PSTX) stock dropped about 34.5% in the after-hours trading on Monday, after a patient died in a prostate cancer drug trial, according to a filing the company made with...
Poseida Therapeutics Inc. shares dropped in the extended session Monday as the biotech drug maker announced a safety trial for a prostate cancer drug had been halted because of a patient death.
Poseida Therapeutics Inc. PSTX, -0.76% shares were halted in the extended session Monday as the biotech drug maker announced a safety trial for a prostate cancer drug had been halted because of a patien...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.
Shares of Poseida Therapeutics Inc. PSTX, 0.00% kicked off their public life with a gain, after the biopharmaceutical company's initial public offering priced at the top of the expected range, but those...
About PSTX
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat rel... [Read more...]
| Industry Biotechnology | IPO Date Jul 10, 2020 |
| CEO Eric Ostertag | Employees 206 |
| Stock Exchange NASDAQ | Ticker Symbol PSTX |
Analyst Forecasts
According to 3 analysts, the average rating for PSTX stock is "Strong Buy." The 12-month stock price forecast is 25.00, which is an increase of 192.40% from the latest price.